Screening for Pancreatic Cancer

Overview

Journal Surg Clin North Am

Specialty General Surgery

Date 2016 Nov 21

PMID 27865274

Citations 8

Authors

Saowanee Ngamruengphong

Marcia Irene Canto

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) is a highly fatal disease that can only be cured by complete surgical resection. However, most patients with PC have unresectable disease at the time of diagnosis, highlighting the need to detect PC and its precursor lesions earlier in asymptomatic patients. Screening is not cost-effective for population-based screening of PC. Individuals with genetic risk factors for PC based on family history or known PC-associated genetic syndromes, however, can be a potential target for PC screening programs. This article provides an overview of the epidemiology and genetic background of familial PC and discusses diagnostic and management approaches.

Citing Articles

Pancreatic cancer detection with a non-contrast MR protocol: is it reliable?.

Maio F, Pasqualino V, Bertana L, Venturini S, Cantoni V, Fusaro M Radiol Med. 2023; 128(9):1035-1046.

PMID: 37515631 PMC: 10474201. DOI: 10.1007/s11547-023-01680-z.

Familial Pancreatic Cancer.

Saba H, Goggins M Gastroenterol Clin North Am. 2022; 51(3):561-575.

PMID: 36153110 PMC: 11095833. DOI: 10.1016/j.gtc.2022.06.006.

Cell-free DNA TAPS provides multimodal information for early cancer detection.

Siejka-Zielinska P, Cheng J, Jackson F, Liu Y, Soonawalla Z, Reddy S Sci Adv. 2021; 7(36):eabh0534.

PMID: 34516908 PMC: 8442905. DOI: 10.1126/sciadv.abh0534.

Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis.

Yao J, Tang Y, Yi B, Yang J, Chai Y, Yin N J Cancer. 2021; 12(11):3164-3179.

PMID: 33976726 PMC: 8100795. DOI: 10.7150/jca.48661.

White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.

Kulkarni N, Mannelli L, Zins M, Bhosale P, Arif-Tiwari H, Brook O Abdom Radiol (NY). 2019; 45(3):729-742.

PMID: 31768594 DOI: 10.1007/s00261-019-02290-y.

References

Struewing J, Abeliovich D, Peretz T, Avishai N, Kaback M, Collins F . The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995; 11(2):198-200. DOI: 10.1038/ng1095-198. View

Springer S, Wang Y, Dal Molin M, Masica D, Jiao Y, Kinde I . A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015; 149(6):1501-10. PMC: 4782782. DOI: 10.1053/j.gastro.2015.07.041. View

Thompson D, Easton D . Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94(18):1358-65. DOI: 10.1093/jnci/94.18.1358. View

Wu J, Matthaei H, Maitra A, Dal Molin M, Wood L, Eshleman J . Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011; 3(92):92ra66. PMC: 3160649. DOI: 10.1126/scitranslmed.3002543. View

Poley J, Kluijt I, Gouma D, Harinck F, Wagner A, Aalfs C . The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009; 104(9):2175-81. DOI: 10.1038/ajg.2009.276. View

Verna E, Hwang C, Stevens P, Rotterdam H, Stavropoulos S, Sy C . Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 16(20):5028-37. DOI: 10.1158/1078-0432.CCR-09-3209. View

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond V . Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009; 302(16):1790-5. PMC: 4091624. DOI: 10.1001/jama.2009.1529. View

Langer P, Kann P, Fendrich V, Habbe N, Schneider M, Sina M . Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009; 58(10):1410-8. DOI: 10.1136/gut.2008.171611. View

Sawai Y, Yamao K, Bhatia V, Chiba T, Mizuno N, Sawaki A . Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy. 2010; 42(12):1077-84. DOI: 10.1055/s-0030-1255971. View

10.

Slater E, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N . PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010; 78(5):490-4. DOI: 10.1111/j.1399-0004.2010.01425.x. View

11.

Sohn T, Yeo C, Cameron J, Hruban R, Fukushima N, Campbell K . Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004; 239(6):788-97. PMC: 1356287. DOI: 10.1097/01.sla.0000128306.90650.aa. View

12.

Lowenfels A, Maisonneuve P, Whitcomb D . Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am. 2000; 84(3):565-73. DOI: 10.1016/s0025-7125(05)70240-6. View

13.

Vasen H, Gruis N, Frants R, van der Velden P, Hille E, Bergman W . Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000; 87(6):809-11. View

14.

Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T . Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy. 2013; 46(1):22-9. DOI: 10.1055/s-0033-1353603. View

15.

Matthaei H, Schulick R, Hruban R, Maitra A . Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(3):141-50. PMC: 3236705. DOI: 10.1038/nrgastro.2011.2. View

16.

Murphy K, Brune K, Griffin C, Sollenberger J, Petersen G, Bansal R . Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002; 62(13):3789-93. View

17.

Shi C, Klein A, Goggins M, Maitra A, Canto M, Ali S . Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res. 2009; 15(24):7737-7743. PMC: 2795080. DOI: 10.1158/1078-0432.CCR-09-0004. View

18.

Hahn S, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B . BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003; 95(3):214-21. DOI: 10.1093/jnci/95.3.214. View

19.

Couch F, Johnson M, Rabe K, Brune K, de Andrade M, Goggins M . The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(2):342-6. DOI: 10.1158/1055-9965.EPI-06-0783. View

20.

Blanco A, de la Hoya M, Osorio A, Diez O, Miramar M, Infante M . Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. PLoS One. 2013; 8(7):e67538. PMC: 3720732. DOI: 10.1371/journal.pone.0067538. View